Objective:To explore the therapeutic effects of the novel wild edible mushroom Astraeus hygrometricus(Pers.)Morgan(A.hygrometricus)on human acute lymphoblastic leukemia cells.Methods:Extensive screening of the antipro...Objective:To explore the therapeutic effects of the novel wild edible mushroom Astraeus hygrometricus(Pers.)Morgan(A.hygrometricus)on human acute lymphoblastic leukemia cells.Methods:Extensive screening of the antiproliferative and chemopreventive potential of different extracts from 5 wild mushrooms,A.hygrometricus,Phallus sp.,Lentinus sp.,Tricholoma sp.,and Serpula sp.was performed against a panel of 6 cancer cell lines and normal cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT)assay.Apoptosis determination,cell cycle profiling,intracellular reactive oxygen species(ROS)and reactive nitrogen species(RNS),and mitochondrial membrane potential were analyzed by flow cytometry.The activity of caspases was measured colorimetrically,and the expression pattern of mitochondrial proteins was analyzed.Results:The methanol extract of A.hygrometricus and MOLT-4 cells were identified as the most potent extract exhibiting antiproliferative activity and most sensitive cell line,respectively.The mushroom extract induced robust selective apoptosis in MOLT-4 cells and arrested cell cycle progression at the G0/G1 stage.The extract disrupted the mitochondrial membrane potential and enhanced ROS production in MOLT-4 cells.The methanol extract induced apoptosis by downregulating the expression of Bcl-2,increasing the expression of Bax,and activating the caspase cascade.Conclusion:The novel wild edible mushroom is a potential repository of biomolecules for the development of antileukemic drugs.展开更多
Glioma and cerebral ischemic stroke are two major events that lead to patient death worldwide.Although these conditions have different physiological incidences,~10%of ischemic stroke patients develop cerebral cancer,e...Glioma and cerebral ischemic stroke are two major events that lead to patient death worldwide.Although these conditions have different physiological incidences,~10%of ischemic stroke patients develop cerebral cancer,especially glioma,in the postischemic stages.Additionally,the high proliferation,venous thrombosis and hypercoagulability of the glioma mass increase the significant risk of thromboembolism,including ischemic stroke.Surprisingly,these events share several common pathways,viz.hypoxia,cerebral inflammation,angiogenesis,etc.,but the proper mechanism behind this co-occurrence has yet to be discovered.The hypercoagulability and presence of the D-dimer level in stroke are different in cancer patients than in the noncancerous population.Other factors such as atherosclerosis and coagulopathy involved in the pathogenesis of stroke are partially responsible for cancer,and the reverse is also partially true.Based on clinical and neurosurgical experience,the neuronal structures and functions in the brain and spine are observed to change after a progressive attack of ischemia that leads to hypoxia and atrophy.The major population of cancer cells cannot survive in an adverse ischemic environment that excludes cancer stem cells(CSCs).Cancer cells in stroke patients have already metastasized,but early-stage cancer patients also suffer stroke for multiple reasons.Therefore,stroke is an early manifestation of cancer.Stroke and cancer share many factors that result in an increased risk of stroke in cancer patients,and vice-versa.The intricate mechanisms for stroke with and without cancer are different.This review summarizes the current clinical reports,pathophysiology,probable causes of co-occurrence,prognoses,and treatment possibilities.展开更多
基金indebted toWest Bengal-Department of Science and Technology(1158[Sanc]/ST BT-13015/15/2021-ST SEC)for project funding,University Grants Commission for providing fellowship and contingency to Ribhu Ray,Indian Council of Medical Research for providing fellowship and contingency to Anirban Chouni and UGC-UPE and UGC-CAS program at the Department of Botany,University of Calcutta for financial support.
文摘Objective:To explore the therapeutic effects of the novel wild edible mushroom Astraeus hygrometricus(Pers.)Morgan(A.hygrometricus)on human acute lymphoblastic leukemia cells.Methods:Extensive screening of the antiproliferative and chemopreventive potential of different extracts from 5 wild mushrooms,A.hygrometricus,Phallus sp.,Lentinus sp.,Tricholoma sp.,and Serpula sp.was performed against a panel of 6 cancer cell lines and normal cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT)assay.Apoptosis determination,cell cycle profiling,intracellular reactive oxygen species(ROS)and reactive nitrogen species(RNS),and mitochondrial membrane potential were analyzed by flow cytometry.The activity of caspases was measured colorimetrically,and the expression pattern of mitochondrial proteins was analyzed.Results:The methanol extract of A.hygrometricus and MOLT-4 cells were identified as the most potent extract exhibiting antiproliferative activity and most sensitive cell line,respectively.The mushroom extract induced robust selective apoptosis in MOLT-4 cells and arrested cell cycle progression at the G0/G1 stage.The extract disrupted the mitochondrial membrane potential and enhanced ROS production in MOLT-4 cells.The methanol extract induced apoptosis by downregulating the expression of Bcl-2,increasing the expression of Bax,and activating the caspase cascade.Conclusion:The novel wild edible mushroom is a potential repository of biomolecules for the development of antileukemic drugs.
基金This work was supported by grants received from DST(NanoMission:DST/NM/NT/2018/105(G)&SR/NM/NS-1058/2015,and SERB:EMR/2017/000992/HS)Govt.of India.
文摘Glioma and cerebral ischemic stroke are two major events that lead to patient death worldwide.Although these conditions have different physiological incidences,~10%of ischemic stroke patients develop cerebral cancer,especially glioma,in the postischemic stages.Additionally,the high proliferation,venous thrombosis and hypercoagulability of the glioma mass increase the significant risk of thromboembolism,including ischemic stroke.Surprisingly,these events share several common pathways,viz.hypoxia,cerebral inflammation,angiogenesis,etc.,but the proper mechanism behind this co-occurrence has yet to be discovered.The hypercoagulability and presence of the D-dimer level in stroke are different in cancer patients than in the noncancerous population.Other factors such as atherosclerosis and coagulopathy involved in the pathogenesis of stroke are partially responsible for cancer,and the reverse is also partially true.Based on clinical and neurosurgical experience,the neuronal structures and functions in the brain and spine are observed to change after a progressive attack of ischemia that leads to hypoxia and atrophy.The major population of cancer cells cannot survive in an adverse ischemic environment that excludes cancer stem cells(CSCs).Cancer cells in stroke patients have already metastasized,but early-stage cancer patients also suffer stroke for multiple reasons.Therefore,stroke is an early manifestation of cancer.Stroke and cancer share many factors that result in an increased risk of stroke in cancer patients,and vice-versa.The intricate mechanisms for stroke with and without cancer are different.This review summarizes the current clinical reports,pathophysiology,probable causes of co-occurrence,prognoses,and treatment possibilities.
